After One Year Of Regulatory Hold, Larimar’s Ataxia Candidate Sees Some Hope
The FDA has cleared the initiation of Larimar Therapeutics Inc’s (NASDAQ:LRMR) 25 mg cohort of Phase 2 trial of CTI-1601 in Friedreich’s…
‘Moderna open to supplying COVID vaccines to China, CEO says’ -Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-believed-pandemic-beginning-that-biontech-violated-patent-ceo-2022-09-14/
Important Biotech Catalysts For September 13, 2022 – End Of The Day Summary
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety…
NGM Bio Presents Updated Preliminary Findings From Ongoing Phase 1b Dose Escalation Trial Of NGM120 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Cancer At AACR Special Conference: Pancreatic Cancer
NGM120 is a novel antagonist antibody that binds GFRAL and inhibits GDF15 signaling for the potential treatment of cancer
NGM120 has been well tolerated to date in patients in the Phase 1b combination cohort (NGM120 +
GENFIT Gets FDA Orphan Drug Status For Liver Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to GENFIT’s (NASDAQ: GNFT) drug candidate GNS5611 (ezurpimtrostat) for the treatment of cholangiocarcinoma.
Conformis Shares Shoot Higher Following FDA Clearance For Actera Hip System
Conformis (NASDAQ: CFMS) has received 510(k) clearance from the U.S. Food and Drug Administration for its Actera Hip System.
Actera utilizes an advanced tri-taper femur stem design that facilitates direct anterior approach total hip arthroplasties, and provides an additional stem option to orthopedic surgeons.
Conformis Actera Hip System Receives 510(k) Clearance From The U.S. FDA
Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced that it has received 510(k) clearance from the U.S. Food and Drug
Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate SY-5609 for the treatment of pancreatic cancer.
Palisade Bio Granted U.S. Patent Titled ‘Administration of serine protease inhibitors to the stomach’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11439611.PN.&OS=PN/1143961
Syros Receives FDA Orphan Drug Designation For SY-5609 For The Treatment Of Pancreatic Cancer
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug